Teva's new migraine drug helps to contain profit fall

TEL AVIV (Reuters) - Israel-based Teva Pharmaceutical Industries Ltd on Thursday forecast a sharp rise in revenue next year from its new migraine drug Ajovy and reported a slightly smaller-than-expected drop in first-quarter profit.The world's largest generic drugmaker is counting on Ajovy and Huntington's treatment Austedo to help revive its fortunes after restructuring to tackle a debt crisis.Sales from its blockbuster multiple sclerosis drug Copaxone have been declining in the face of..